三苯乙酸维兰特罗(Vilanterol Trifenatate) - 药物靶点：β2-adrenergic receptor_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Vilanterol、Vilanterol trifenatate (JAN/USAN)、GSK-642444

+ [8]

靶点

β2-adrenergic receptor

作用机制

β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂)

治疗领域

免疫系统疾病心血管疾病呼吸系统疾病+ [1]

在研适应症-

非在研适应症

气道病变哮喘心血管疾病+ [3]

原研机构

GSK Plc

在研机构-

非在研机构

GSK Plc

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

结构

分子式C44H49Cl2NO7

InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N

CAS号503070-58-4

关联

97

项与三苯乙酸维兰特罗相关的临床试验

CTRI/2024/08/073060 / Not yet recruiting临床4期

A Multi-Centric, Active Post Marketing Surveillance Study to Assess the Safety and Efficacy of Fluticasone Furoate and Vilanterol Powder for Inhalation for the Treatment of Patients with Asthma - NIL

开始日期2024-09-07

申办/合作机构-

NCT06552364 / Not yet recruiting临床4期IIT

Air Pollution and Inhaled Corticosteroids in COPD

Studies have shown that people with chronic obstructive pulmonary disease (COPD) have worse symptoms after breathing polluted air. People with COPD also often need to go to the hospital if they get a virus or other bug. One of the main drugs taken for COPD treatment (inhaled corticosteroid) may change COPD patients' lungs in ways that make it harder to deal with bugs, especially if they breathe in polluted air. If so, this could cause more frequent hospital visits. On the other hand, the same drug (inhaled corticosteroid) helps some people control symptoms, and may help them avoid hospital visits. The APEL investigators are conducting this study (APIC) to understand if this drug (inhaled corticosteroid), in combination with polluted air, will change the lungs of those with COPD in ways that make it more likely to catch bugs or have other problems.

开始日期2024-09-01

申办/合作机构

University of British Columbia

[+4]

CTRI/2024/06/069544 / Recruiting临床4期

A Multicenter, Prospective, Open Label, Single arm, Phase IV Study to Assess the Safety and Effectiveness of Fixed Dose Combination of Vilanterol Trifenatate eq. to 25 mcg Vilanterol 40 mcg and Glycopyrronium Bromide eq. to 50 mcg Glycopyrronium 63 mcg Powder for Inhalation in Capsule indicated as maintenance treatment for Patients with Chronic Obstructive Pulmonary Disease. - NA

开始日期2024-07-07

申办/合作机构

Lupin Ltd

100 项与三苯乙酸维兰特罗相关的临床结果

登录后查看更多信息

100 项与三苯乙酸维兰特罗相关的转化医学

登录后查看更多信息

100 项与三苯乙酸维兰特罗相关的专利（医药）

登录后查看更多信息

518

项与三苯乙酸维兰特罗相关的文献（医药）

2024-10-01·JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Comparison of the Genomic Activity of an EP₄-Receptor and β₂-Adrenoceptor Agonist in BEAS-2B Human Bronchial Epithelial Cells: In Search of Compartmentalized, cAMP-Dependent Gene Expression

Article

作者: Mostafa, Mahmoud M ; Hamed, Omar ; Giembycz, Mark A ; Joshi, Radhika ; Paracha, Tamkeen U ; Jayasinghe, Varuna ; Thorne, Andrew J ; Yan, Dong ; Newton, Robert

It has been proposed that inhaled E-prostanoid 4 (EP₄)-receptor agonists could represent a new class of bronchodilators for the treatment of asthma that are as effective as β ₂-adrenoceptor agonists. However, the genomic impact of such drugs is unknown despite being potentially deleterious to respiratory health. Herein, we used mRNA-seq to compare the transcriptomic responses produced by 2-[3-[(1R,2S,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-5-[2-(methoxymethyl)phenyl]pent-1-enyl]-5-oxo-cyclopentyl]sulphanylpropylsulphanyl] acetic acid (ONO-AE1-329; an EP₄-receptor agonist) and vilanterol (a β ₂-adrenoceptor agonist) in BEAS-2B human airway epithelial cells. We also determined if an increase in cAMP mediated by different G protein-coupled receptors (GPCRs) promoted distinct transcriptional signatures by expanding this inquiry to include the adenosine A_2B- and I-prostanoid receptor agonists, 2-[[6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]-2-pyridinyl]thio]-acetamide (Bay60-6583) and taprostene, respectively. Maximally-effective concentrations of ONO-AE1-329 and vilanterol significantly regulated (q ≤ 0.05; ≥1.5-/≤0.67-fold) 232 and 320 genes, respectively of which 217 were shared. Spearman analysis showed these gene expression changes to be highly rank order correlated, indicating that the functional overlap between the two interventions should be considerable. Unexpectedly, the genomic effects of ONO-AE1-329, vilanterol, Bay 60-6583, and taprostene were also highly rank order correlated. This finding suggests that cAMP generated by any GPCR would initiate the same transcriptional program. Nevertheless, relative to vilanterol, ONO-AE1-329 typically behaved as a partial agonist that varied across transcripts. These data indicate that each ONO-AE1-329-regulated gene differs in sensitivity to cAMP and is defined by a unique receptor occupancy-response relationship. Moreover, if this relatively modest genomic response in BEAS-2B cells is retained in vivo, then inhaled EP₄-receptor agonists could represent an alternative, and possibly safer, class of bronchodilators. SIGNIFICANCE STATEMENT: The genomic consequences of β ₂-adrenoceptor agonists in asthma are often overlooked despite being potentially harmful to lung health. We determined that ONO-AE1-329, an EP₄-receptor agonist and effective bronchodilator, produced gene expression changes in BEAS-2B cells that were typically modest relative to the β ₂-adrenoceptor agonist vilanterol. Furthermore, ONO-AE1-329 behaved as a partial agonist that varied across transcripts. If this genomic activity is reproduced in vivo, then EP₄-receptor agonists could represent an alternative, and possibly safer, class of bronchodilators.

2024-09-01·RESPIRATORY MEDICINE

The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada – The IMPACT trial

Article

作者: Martin, Alan ; Shah, Dhvani ; Mursleen, Sara ; Ismaila, Afisi S ; Risebrough, Nancy A ; Ndirangu, Kerigo ; Schroeder, Melanie

BACKGROUND:

This cost-utility analysis assessed the long-term clinical and economic benefits of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy vs FF/VI or UMEC/VI from a Quebec societal perspective in patients with chronic obstructive pulmonary disease (COPD) with ≥1 moderate/severe exacerbation in the previous year.

METHODS:

The validated GALAXY disease progression model was utilized, with parameters set to baseline and efficacy data from IMPACT. Treatment costs (2017 Canadian dollars [C$]) were estimated using Quebec-specific unit costs. Costs and health outcomes were discounted at 1.5 %/year. A willingness-to-pay threshold of C$50,000/quality-adjusted life year (QALY) was considered cost-effective. Outcomes modeled were exacerbation rates, QALYs, life years (LYs), costs and incremental cost-effectiveness ratios (ICERs). Subgroup analyses were performed according to prior treatment, exacerbation history in the previous year, and baseline lung function.

RESULTS:

Over a lifetime horizon, FF/UMEC/VI resulted in more QALYs and LYs gained, at a small incremental cost compared with FF/VI and UMEC/VI. From a societal perspective, the estimated ICER for the base case was C$18,152/QALY vs FF/VI, and C$15,847/QALY vs UMEC/VI. For the subgroup analyses (FF/UMEC/VI compared with FF/VI and UMEC/VI), ICERs ranged from: C$17,412-25,664/QALY and C$16,493-18,663/QALY (prior treatment); C$15,247-19,924/QALY and C$15,444-28,859/QALY (exacerbation history); C$14,025-34,154/QALY and C$16,083-17,509/QALY (baseline lung function).

INTERPRETATION:

FF/UMEC/VI was predicted to improve outcomes and be cost-effective vs both comparators in the base case and all subgroup analyses, and based on this analysis would be an appropriate investment of health service funds in Quebec.

CLINICAL TRIAL REGISTRATION NUMBER:

IMPACT trial NCT02164513.

2024-09-01·Journal of Allergy and Clinical Immunology-In Practice

Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study

Article

作者: Peachey, Guy ; Slade, David ; Kerwin, Edward ; Zarankaite, Agne ; Nathan, Robert A ; Pizzichini, Emilio ; Pavord, Ian D ; Moore, Alison ; Kerstjens, Huib A ; Hanania, Nicola A ; Boulet, Louis-Philippe ; Oppenheimer, John

BACKGROUND:

Limited data exist on the relative impact of moderate and severe exacerbations on asthma control and impairment.

OBJECTIVE:

To explore data from the CAPTAIN trial to evaluate the relationship between first moderate or severe exacerbation and changes in lung function, symptoms, physical activity limitation scores, and short-acting β₂-agonist (SABA) usage to determine the clinical relevance of moderate events.

METHODS:

CAPTAIN was a phase IIIA 24- to 52-week, multicenter, international, randomized controlled trial evaluating efficacy and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in patients with uncontrolled asthma on inhaled corticosteroid/long-acting β₂-agonist. Outcomes reported include first postrandomization exacerbation event by severity (wk 1-52), frequency and duration of moderate and severe exacerbations, and time course of changes over ± 14-day peri-exacerbation period for lung function, symptoms, limitations, and SABA use.

RESULTS:

Of the intent-to-treat population (n = 2,436), 550 patients (23%) continued to 52 weeks. There were 529 moderate and 546 severe exacerbations. Lung function changes were similar, but symptom, physical activity limitation scores, and SABA use were higher, for severe versus moderate exacerbations. Lung function decline preceded increases in symptom, physical activity limitation scores, and SABA use, irrespective of exacerbation severity. Lung function variables, limitation scores, and SABA use returned to pre-exacerbation baseline after approximately 8 to 12 days for both exacerbation severities.

CONCLUSIONS:

Whereas severe events were associated with greater impact on symptoms, physical activity limitations, and SABA use, onset and time to resolution were generally similar for moderate and severe events. Both exacerbation severities represent clinically important deteriorations comprising clinical and functional changes.

35

项与三苯乙酸维兰特罗相关的新闻（医药）

2024-06-12

·BioSpace

Teva Loses Inhaler Patent Case Against Amneal, Must Delete or Amend Orange Book Listing

Pictured: Facade of a U.S. courthouse/iStock, PierreDesrosiers A New Jersey federal court on Monday ruled against Teva Pharmaceuticals, finding that five key patents for its inhaler product ProAir HFA (albuterol sulfate) are “improperly listed” on the FDA’s Orange Book. District Judge Stanley Chesler agreed with the plaintiffs—Amneal Pharmaceuticals, with the backing of the FTC—that Teva’s patents only apply to the inhaler device of ProAir HFA and not to its albuterol sulfate drug formulation. The judge ruled that Teva’s inhaler patents do not claim a “finished dosage form” of albuterol, allowing Amneal to develop a generic version of the drug. “It is undisputed that no claim in any of the Inhaler Patents discloses albuterol sulfate,” Chesler wrote in his decision, adding that Teva must either “correct or delete” its patent listings in the FDA’s Orange Book to reflect the court’s judgement. Amneal in July 2023 submitted an Abbreviated New Drug Application (ANDA) for a generic version of ProAir HFA, though its filing specifically focused on inhalable albuterol sulfate. Teva in 2023 sued Amneal, claiming that the ANDA infringed on its patent protection for its drug-device combination product. Amneal filed a countersuit soon after claiming that Teva’s patents should not have been listed on the Orange Book in the first place. Teva’s lawsuit focuses on five key patents, dubbed the ‘712, ‘289, ‘587, ‘808 and ‘889 patents. Together, these patents protect aspects of Teva’s inhaler device and its metered dose system. However, in its suit, the pharma sought to expand this coverage to also include the albuterol formulation that the inhaler delivers. In his opinion, Chesler agreed with Teva that the term “drug” has a “broad scope” and could include devices or other components “intended for use for the treatment of disease.” However, the Orange Book’s listing statute modifies this definition with the restrictive phrase “for which the applicant submitted the application,” which Chesler argues nullifies Teva’s argument. “The fact that the statutory definition of ‘drug’ expressly includes devices for treating disease, and their components, does not nullify the restrictive action of the modifying phrase, ‘for which the applicant submitted the application,’” Chesler wrote. Monday’s ruling comes as the FTC is ramping up its scrutiny of “junk” patents listed on the FDA’s Orange Book. The antitrust watchdog launched its initial salvo in November 2023, challenging more than 100 patents by companies including AbbVie, GSK and Teva. The FTC’s opening campaign included a wide range of pharmaceutical products, including autoinjectors and inhalers. In April 2024, the FTC sent a warning letter to Novo Nordisk calling into question the patent of its blockbuster diabetes drug Ozempic (semaglutide). The federal agency also wrote to GSK to raise concerns about its asthma inhaler Trelegy Ellipta (fluticasone, umeclidinium, vilanterol). Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

专利侵权

2024-05-01

·BioSpace

FTC Targets ‘Junk’ Patents Including Novo’s Ozempic, GSK’s Trelegy Ellipta and Other Drugs

Pictured: Entrance to the FTC's office in Washington, DC/iStock, hapabapa The U.S. Federal Trade Commission on Tuesday sent warning letters to 10 pharmaceutical companies, challenging patents for several drugs including Novo Nordisk’s blockbuster diabetes treatment Ozempic (semaglutide) and GSK’s asthma inhaler Trelegy Ellipta (fluticasone, umeclidinium, vilanterol). The FTC is challenging the patents of 20 different brand name products, claiming that their listings in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations—more commonly known as the Orange Book—are improper or inaccurate. “By filing bogus patent listings, pharma companies block competition and inflate the cost of prescription drugs, forcing Americans to pay sky-high prices for medicines they rely on,” FTC Chair Lina Khan said in a statement. “By challenging junk patent filings, the FTC is fighting these illegal tactics and making sure that Americans can get timely access to innovative and affordable versions of the medicines they need,” Khan added. In addition to Ozempic and Trelegy Ellipta, the FTC’s latest round of patent challenges also targets Novo’s Saxenda (liraglutide) and Victoza (liraglutide)—both indicated for type 2 diabetes—and Novartis’ inhaler products Seebri Breezhaler (glycopyrronium bromide) and Utibron Neohaler (indacaterol and glycopyrrolate), approved for chronic obstructive pulmonary disease. The pharma companies now have 30 days to either withdraw or amend their disputed listings, or confirm “under penalty or perjury” that these patents indeed comply with the statutory and regulatory requirements. A GSK spokesperson in a statement to Endpoints News said that the company is reviewing the FTC’s letter. GSK takes “the FTC’s views seriously; however, we will also do our own analysis as the law requires. Once complete, we will respond to the FDA and FTC.” Meanwhile, a Boehringer Ingelheim spokesperson said that the pharma “has never wrongfully submitted patents for listing in the Orange Book.” Tuesday’s warnings follow an initial salvo in November 2023, when the FTC challenged more than 100 patents by 10 pharma companies including AbbVie, AstraZeneca and subsidiaries of GSK and Teva Pharmaceuticals. At the time, the antitrust watchdog targeted a wide range of pharmaceutical products, including inhaler devices, multidose bottles and epinephrine autoinjectors. Aside from the FTC, members of Congress have also started targeting the high cost of medication in the U.S., paying particular attention to Ozempic. Last week, Sen. Bernie Sanders (I-Vt.), chair of the Senate health committee, launched a probe into the ‘outrageously high prices’ of Ozempic, as well as its sister weight-loss therapy Wegovy (semaglutide). Sanders in a letter to Novo CEO Lars Fruergaard Jørgensen asked for additional information regarding Ozempic and Wegovy, including revenue, prices paid by public and private payers, R&D spending and the pharma’s tactics to extend their exclusivity. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

专利到期

2024-04-05

·Pharmaceutical Technology

GSK expands Asia-Pacific reach for Trelegy Ellipta with Singapore approval

Trelegy Ellipta is approved as a maintenance treatment for COPD and asthma in the US. Image Credit: MAXSHOT.PL / Shutterstock. Singapore’s Health Sciences Authority (HSA) has expanded the label of GlaxoSmithKline (GSK)’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to include its use as a maintenance therapy for adults with asthma. The Singapore agency also approved a new dosage strength for the inhaled therapy in asthma. In 2019, HSA approved Trelegy Ellipta as a maintenance therapy for relieving moderate to severe exacerbations in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is approved as a maintenance treatment for COPD in multiple regions including the US, Europe and China. However, the drug has also been approved for treating asthma in a few countries such as the US. Trelegy Ellipta pulled in £2.2bn ($2.8bn) in global sales for GSK in 2023, as per the company’s financials. The drug sales are expected to rise, with Trelegy Ellipta expected to generate approximately $3.8bn in global sales in 2027, according to a GlobalData analysis. GlobalData is the parent company of Pharmaceutical Technology . Last month, GSK announced plans to cap out-of-pocket costs for eligible patients at $35 per month for its COPD and asthma medications in light of the rising drug prices in the US. Trelegy Ellipta is one of the drugs included in GSK’s programme, which will be implemented across the country no later than 1 January 2025. See Also: UK MHRA approves Advanz Pharma antibiotic for complex infections Japan’s PMDA approves Partner’s inhaled Leukine for aPAP Another therapy looking to target both asthma and COPD populations is Amgen and AstraZeneca ’s Tezspire (tezepelumab-ekko). The monoclonal antibody has been approved for treating severe asthma in multiple countries including the US. The companies are evaluating the therapy in patients with moderate to severe COPD in a placebo-controlled Phase II trial (NCT04039113). Data from the trial is expected in H1 this year. Regeneron Pharmaceuticals and Sanofi are also seeking approval for their monoclonal antibody , Dupixent (dupilumab) as a maintenance therapy for COPD. The US Food and Drug Administration (FDA) has set a target action date of 27 June for an approval decision. Dupixent is approved for treating atopic dermatitis , asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis.

上市批准临床2期

100 项与三苯乙酸维兰特罗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09697	三苯乙酸维兰特罗	-	DB09082

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
动脉僵硬	临床3期	美国	GSK Plc	2011-03-04
动脉僵硬	临床3期	德国	GSK Plc	2011-03-04
动脉僵硬	临床3期	挪威	GSK Plc	2011-03-04
动脉僵硬	临床3期	菲律宾	GSK Plc	2011-03-04
动脉僵硬	临床3期	韩国	GSK Plc	2011-03-04
动脉僵硬	临床3期	泰国	GSK Plc	2011-03-04
心血管疾病	临床3期	美国	GSK Plc	2011-01-25
心血管疾病	临床3期	中国	GSK Plc	2011-01-25
心血管疾病	临床3期	日本	GSK Plc	2011-01-25
心血管疾病	临床3期	阿根廷	GSK Plc	2011-01-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ERS2019	N/A	哮喘	510	Vilanterol	獵齋淵顧艱窪構醖鑰齋(蓋夢壓廠膚築鬱襯鏇膚) = 觸遞選蓋願構窪鬱襯齋獵構壓網醖選襯鹽積製 (壓餘鬱積醖範齋窪製獵 ) 更多	不佳	2019-09-28
				Placebo	獵齋淵顧艱窪構醖鑰齋(蓋夢壓廠膚築鬱襯鏇膚) = 鏇遞窪糧蓋範壓製窪遞獵構壓網醖選襯鹽積製 (壓餘鬱積醖範齋窪製獵 ) 更多
NCT01957150 (CTgov)	临床4期	慢性阻塞性肺疾病	283	VI (Participants Administered VI)	壓簾膚製憲蓋窪醖獵壓(鏇鏇積製齋鹹蓋衊壓廠) = 鹹蓋齋網衊鹽顧網餘積簾鹽觸壓簾醖蓋鬱願願 (網艱鏇構鑰鏇艱築夢範, 顧夢衊製淵餘獵淵網餘 ~ 淵積鹽壓網鬱襯積廠淵) 更多	-	2019-04-10
				VI (Participants Administered FF/VI)	壓簾膚製憲蓋窪醖獵壓(鏇鏇積製齋鹹蓋衊壓廠) = 願範繭遞醖觸膚遞醖遞簾鹽觸壓簾醖蓋鬱願願 (網艱鏇構鑰鏇艱築夢範, 遞淵獵顧築廠觸遞糧膚 ~ 艱憲獵醖鏇網觸顧襯範) 更多
NCT02446418 (CTgov)	临床3期	持续性哮喘	423	ICS (Usual ICS/LABA)	構齋築夢糧製獵網鹹糧(襯襯窪觸襯觸壓築繭壓) = 積壓壓製窪醖願齋廠鑰窪衊網獵範夢願壓製蓋 (廠築膚鹽壓積鹽壓築鏇, 憲衊糧製鬱醖遞鬱構醖 ~ 願構衊衊遞鑰夢醖繭鏇) 更多	-	2019-01-14
				VI+Vilanterol (FF/VI)	構齋築夢糧製獵網鹹糧(襯襯窪觸襯觸壓築繭壓) = 鑰繭鹹構觸蓋範遞餘範窪衊網獵範夢願壓製蓋 (廠築膚鹽壓積鹽壓築鏇, 願艱艱膚繭膚鑰壓鹽窪 ~ 積膚積願觸願餘鬱夢鹽) 更多
NCT02712047 (CTgov)	临床2期	哮喘 \| 气道病变	28	Placebo	鹹餘製醖夢獵醖憲廠憲(壓齋製蓋鬱構顧觸夢艱) = 構願壓襯襯齋醖築艱鹽觸蓋鹽觸製襯齋選鏇襯 (窪鬱壓襯範憲淵鏇鑰網, 蓋築蓋鬱鹹餘膚積積醖 ~ 築鹽鬱繭齋鏇願齋鑰艱) 更多	-	2018-08-28
NCT00372112 (CTgov)	临床2期	慢性阻塞性肺疾病	68	Placebo+GW642444	蓋鹹醖築廠鏇獵衊顧艱(鹹積鑰糧鬱餘窪艱廠鬱) = 廠鑰製顧壓艱範觸淵遞衊衊鬱鑰憲簾遞廠膚鹽 (觸觸選鬱衊築壓積襯糧, 艱糧願齋糧醖觸蓋淵醖 ~ 鑰築膚鏇廠窪鏇夢範醖) 更多	-	2018-02-22
NCT01313676 (SUMMIT, Pubmed)	临床3期	中度慢性阻塞性肺疾病	16,568	Fluticasone Furoate	(衊選齋鑰窪選艱衊鹽鹽) = 範襯醖壓窪網簾構鏇淵糧齋製壓選醖構積鹽襯 (鏇觸範廠選繭醖餘鏇夢 )	-	2018-01-01
				Vilanterol	(衊選齋鑰窪選艱衊鹽鹽) = 壓積顧衊簾觸蓋夢鑰鏇糧齋製壓選醖構積鹽襯 (鏇觸範廠選繭醖餘鏇夢 )
NCT01313676 (SUMMIT, CTgov)	临床3期	慢性阻塞性肺疾病 \| 心血管疾病	16,568	Placebo	夢醖鏇廠齋築鹽襯襯範(範鏇艱餘憲衊繭築網繭) = 淵餘糧願築築繭鑰構範憲獵範鑰築壓顧膚觸積 (範夢糧選鑰衊顧選膚顧, 淵鏇遞襯衊憲獵顧廠製 ~ 繭觸範範膚觸鬱鏇簾鏇) 更多	-	2016-08-09
NCT02105974 (GlaxoSmithKline 200820 \| GlaxoSmithKline, CTgov)	临床3期	慢性阻塞性肺疾病	1,621	FF (FF/VI 100/25 µg QD)	襯積夢網糧築淵淵窪淵(憲觸構選衊鬱願蓋製構) = 築鏇鏇窪齋範鑰選夢築繭醖顧鏇顧鹹獵糧鹹構 (積獵襯壓製襯齋選遞壓, 築繭醖膚艱鑰憲製糧膚 ~ 觸窪簾願夢窪廠膚簾餘) 更多	-	2016-04-13
				albuterol (salbutamol)+oxitropium bromide (VI 25 µg QD)	襯積夢網糧築淵淵窪淵(憲觸構選衊鬱願蓋製構) = 選窪願製糧夢選蓋醖襯繭醖顧鏇顧鹹獵糧鹹構 (積獵襯壓製襯齋選遞壓, 齋鏇齋醖網積選顧觸鏇 ~ 鹽顧繭簾積壓膚製獵鏇) 更多
NCT01691885 (Pubmed \| Am J Respir Crit Care Med) 人工标引	临床3期	慢性阻塞性肺疾病	45	fluticasone furoate+vilanterol	鏇鹹壓鑰簾範壓鹽襯齋(積築餘簾膚蓋壓鹽鬱鬱) = 淵鹽鑰壓觸顧醖網積遞顧蓋襯鹹衊膚鑰廠簾糧 (鹹壓鑰膚鑰淵觸構範網, 2.74-8.91) 更多	积极	2016-04-01
				Placebo	-
NCT01336608 (CTgov)	临床3期	慢性阻塞性肺疾病 \| 动脉僵硬	446	Placebo (Placebo QD)	繭壓醖艱鬱齋網膚繭窪(築膚網鹹壓顧壓觸醖蓋) = 築構醖獵廠遞築窪願選衊膚鏇獵獵醖繭鏇遞鹽 (糧齋網選顧齋觸簾壓齋, 壓鬱選製鹽顧網齋糧鬱 ~ 鹹遞觸餘壓襯淵膚網觸) 更多	-	2015-07-10
				albuterol (salbutamol) (VI 25 µg QD)	繭壓醖艱鬱齋網膚繭窪(築膚網鹹壓顧壓觸醖蓋) = 襯積鹹襯鹽鬱鏇艱顧觸衊膚鏇獵獵醖繭鏇遞鹽 (糧齋網選顧齋觸簾壓齋, 糧淵製遞蓋憲襯膚鹹醖 ~ 製繭網鑰醖鹹廠廠遞鏇) 更多